Strong Performance of Health-Focused Dividend ETF
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Source: NASDAQ.COM
- Annual Returns: The Schwab U.S. Dividend Equity ETF has achieved an average annual gain of 13.37% over the past decade, demonstrating robust performance in a volatile market, appealing to investors seeking stable returns.
- Dividend Yield: With a recent dividend yield of 3.3%, this ETF not only provides a steady cash flow but also offers the potential for capital appreciation, making it suitable for defensive investing in uncertain economic conditions.
- Investment Returns: Investing $1,200 annually with an assumed annual return of 10% could yield approximately $68,730 in 20 years, highlighting the power of compounding and encouraging a focus on long-term holding strategies.
- Portfolio Composition: The ETF holds around 100 stocks, primarily blue-chip companies, with top holdings like Lockheed Martin and Coca-Cola, further enhancing the stability and income potential of its investment portfolio.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.910
Low
95.00
Averages
119.53
High
139.00
Current: 115.910
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Dividend ETF Recommendation
- Dividend Yield: The Schwab U.S. Dividend Equity ETF (SCHD) recently offers a dividend yield of 3.3%, providing a stable income source amidst current economic uncertainties, appealing to defensive investors.
- Historical Performance: Since its inception in 2011, the ETF has achieved an average annual return of 13.30%, with a 15.67% return over the past year, demonstrating strong performance in volatile markets and boosting investor confidence.
- Portfolio Strength: SCHD holds approximately 100 stocks, including blue-chip companies like Lockheed Martin, Coca-Cola, and PepsiCo, ensuring investment diversity and stability, thereby providing long-term capital appreciation potential for investors.
- Long-Term Investment Returns: Investing $1,200 annually, with an assumed annual return of 10%, could yield around $68,730 after 20 years, highlighting the ETF's appeal as a long-term investment vehicle.
See More
Strong Performance of Health-Focused Dividend ETF
- Annual Returns: The Schwab U.S. Dividend Equity ETF has achieved an average annual gain of 13.37% over the past decade, demonstrating robust performance in a volatile market, appealing to investors seeking stable returns.
- Dividend Yield: With a recent dividend yield of 3.3%, this ETF not only provides a steady cash flow but also offers the potential for capital appreciation, making it suitable for defensive investing in uncertain economic conditions.
- Investment Returns: Investing $1,200 annually with an assumed annual return of 10% could yield approximately $68,730 in 20 years, highlighting the power of compounding and encouraging a focus on long-term holding strategies.
- Portfolio Composition: The ETF holds around 100 stocks, primarily blue-chip companies, with top holdings like Lockheed Martin and Coca-Cola, further enhancing the stability and income potential of its investment portfolio.
See More
Companies Like Monster, Palantir, and Expedia That Can Withstand Market Turbulence
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Volatility on Wall Street: The market remains volatile, prompting equity strategists to seek out resilient stocks that can withstand the current economic pressures.
See More
Stocks Like Monster Beverage and Expedia Poised to Endure Market Fluctuations with Higher Profit Margins.
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Strategic Response: Equity strategists at CIBC Capital Markets are identifying stocks that may remain resilient in the current volatile market conditions.
See More
Pfizer Stock Shows Signs of Reversal Potential
- Technical Reversal Signals: Pfizer's stock has formed a series of higher lows over the past year, breaking above its downtrend since the 2024 peak, indicating potential for a reversal that may provide investors with a timely re-entry opportunity.
- Defined Support Levels: The stock's downside support is clearly defined around the rising 50-day moving average, forming an ascending triangle with a breakout target of $30.50, suggesting a favorable risk/reward scenario in the current market environment.
- Improving Momentum Indicators: The Relative Strength Index (RSI) is trending higher and not overbought, indicating enhanced buying momentum, allowing investors to consider buying on recent weakness to capitalize on a potential rally above $27.50 towards $30.
- Safe Dividend Yield: With a current dividend yield of 6.4%, Pfizer, as part of the large pharma sector, may serve as a safe haven for investors amid increasing market volatility, providing stable returns with relatively low risk.
See More
Analysis of VLUE ETF's 52-Week Price Fluctuations
- Price Range Analysis: The VLUE ETF's 52-week low is $91.80 per share, with a high of $154.31, and the latest trade at $146.48 indicates relative stability in a volatile market, potentially attracting risk-averse investors.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and optimize investment timing, thereby enhancing decision-making.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, offering flexibility that makes ETFs ideal for diversified portfolios.
- Liquidity Monitoring: Weekly monitoring of changes in shares outstanding allows for tracking significant inflows (new units created) or outflows (old units destroyed), which impacts the ETF's underlying holdings and can influence market performance and investor confidence.
See More
Strong Dividend ETF Recommendation
- Dividend Yield: The Schwab U.S. Dividend Equity ETF (SCHD) recently offers a dividend yield of 3.3%, providing a stable income source amidst current economic uncertainties, appealing to defensive investors.
- Historical Performance: Since its inception in 2011, the ETF has achieved an average annual return of 13.30%, with a 15.67% return over the past year, demonstrating strong performance in volatile markets and boosting investor confidence.
- Portfolio Strength: SCHD holds approximately 100 stocks, including blue-chip companies like Lockheed Martin, Coca-Cola, and PepsiCo, ensuring investment diversity and stability, thereby providing long-term capital appreciation potential for investors.
- Long-Term Investment Returns: Investing $1,200 annually, with an assumed annual return of 10%, could yield around $68,730 after 20 years, highlighting the ETF's appeal as a long-term investment vehicle.
See More
Strong Performance of Health-Focused Dividend ETF
- Annual Returns: The Schwab U.S. Dividend Equity ETF has achieved an average annual gain of 13.37% over the past decade, demonstrating robust performance in a volatile market, appealing to investors seeking stable returns.
- Dividend Yield: With a recent dividend yield of 3.3%, this ETF not only provides a steady cash flow but also offers the potential for capital appreciation, making it suitable for defensive investing in uncertain economic conditions.
- Investment Returns: Investing $1,200 annually with an assumed annual return of 10% could yield approximately $68,730 in 20 years, highlighting the power of compounding and encouraging a focus on long-term holding strategies.
- Portfolio Composition: The ETF holds around 100 stocks, primarily blue-chip companies, with top holdings like Lockheed Martin and Coca-Cola, further enhancing the stability and income potential of its investment portfolio.
See More
Companies Like Monster, Palantir, and Expedia That Can Withstand Market Turbulence
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Volatility on Wall Street: The market remains volatile, prompting equity strategists to seek out resilient stocks that can withstand the current economic pressures.
See More
Stocks Like Monster Beverage and Expedia Poised to Endure Market Fluctuations with Higher Profit Margins.
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Strategic Response: Equity strategists at CIBC Capital Markets are identifying stocks that may remain resilient in the current volatile market conditions.
See More
Pfizer Stock Shows Signs of Reversal Potential
- Technical Reversal Signals: Pfizer's stock has formed a series of higher lows over the past year, breaking above its downtrend since the 2024 peak, indicating potential for a reversal that may provide investors with a timely re-entry opportunity.
- Defined Support Levels: The stock's downside support is clearly defined around the rising 50-day moving average, forming an ascending triangle with a breakout target of $30.50, suggesting a favorable risk/reward scenario in the current market environment.
- Improving Momentum Indicators: The Relative Strength Index (RSI) is trending higher and not overbought, indicating enhanced buying momentum, allowing investors to consider buying on recent weakness to capitalize on a potential rally above $27.50 towards $30.
- Safe Dividend Yield: With a current dividend yield of 6.4%, Pfizer, as part of the large pharma sector, may serve as a safe haven for investors amid increasing market volatility, providing stable returns with relatively low risk.
See More
Analysis of VLUE ETF's 52-Week Price Fluctuations
- Price Range Analysis: The VLUE ETF's 52-week low is $91.80 per share, with a high of $154.31, and the latest trade at $146.48 indicates relative stability in a volatile market, potentially attracting risk-averse investors.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and optimize investment timing, thereby enhancing decision-making.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, offering flexibility that makes ETFs ideal for diversified portfolios.
- Liquidity Monitoring: Weekly monitoring of changes in shares outstanding allows for tracking significant inflows (new units created) or outflows (old units destroyed), which impacts the ETF's underlying holdings and can influence market performance and investor confidence.
See More
